Breast Cancer Clinical Trials: The Landscape at the Uganda Cancer Institute and Lessons Learned

Manoj P. Menon, MD1,2,3; Nixon Niyonzima, MBChB, MSc, PhD1,4; Julie Gralow, MD1,2,3; and Jackson Orem, MBChB, MMed, PhD4

abstract

The Uganda Cancer Institute, the sole national comprehensive cancer center in Uganda, has a long and rich history of clinical investigation and locally relevant cancer research. Given the increasing burden of breast cancer in Uganda and elsewhere in sub-Saharan Africa (SSA) and driven by the limited availability of immunohistochemistry (IHC), we launched a clinical trial aimed at evaluating locally available diagnostics to detect the presence of hormone receptors (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2. Preliminary data from 32 women in the diagnostic component of the study reveal high sensitivity and specificity for estrogen receptor and progesterone receptor and high specificity for human epidermal growth factor receptor 2 when comparing reverse transcriptase polymerase chain reaction with the gold standard (IHC). Innovative diagnostic and treatment strategies are required to address the burden of breast cancer that is increasing throughout SSA. Given the costs, infrastructure, and trained personnel associated with IHC, alternative testing options (including reverse transcriptase polymerase chain reaction as tested in our study) may provide an expedited and cost-effective method to determine receptor testing in breast cancer. Clinical trials conducted in the local setting are critical to determining optimal strategies for effective breast cancer management in SSA.

JCO Global Oncol 7:127-132. © 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License

BACKGROUND

Cancer is an emerging health threat in resource-limited countries, including sub-Saharan Africa (SSA), where its morbidity and mortality are expected to exceed the burden in resource-rich regions in 2020.1 Multiple factors, including advanced stage at presentation, limited diagnostic capacity, therapeutic options, and access to clinical trials and novel therapies are responsible for this disparity.2,3

The Uganda Cancer Institute (UCI), the sole national comprehensive cancer center in Uganda, has a long and rich history of clinical investigation and locally relevant cancer research, with an aim of reducing these health disparities. Cancer research in Uganda dates back to the work of Sir Albert Cook and the subsequent research of Sir Denis Burkitt, which helped elucidate the pathogenesis and role of viral oncogenesis and revolutionized the role of combination chemotherapy globally.9-13 Burkitt Lymphoma, one of the virus-associated cancers eponymously named after Dr Denis Burkitt, was first described by researchers in Uganda.14 Among many other achievements, researchers at the UCI have described the epidemiology of hepatocellular carcinoma, including documenting the relative young age of patients, as well as the presence of advanced disease, when compared with patients in Western Europe and North America, and the benefit of doxorubicin in this setting.15 Given the unavailability of radiation therapy in Uganda at the time, Olweny et al16 demonstrated the role of combination chemotherapy in pediatric Hodgkin’s disease. Indeed, the motto of the UCI is “Research is our resource” to highlight the important role of research in managing patients with cancer.

More recently, given the dual burden of HIV and cancer, colleagues at the UCI recognized the need for less myelotoxic chemotherapeutic options and more pragmatic treatment options among patients with HIV-associated malignancies. Consequently, a prospective study of treatment of two cycles (every 6 weeks) of an oral regimen consisting of lomustine (day 1), etoposide (days 1-3), cyclophosphamide (days 22-26), and procarbazine (days 22-26) was used for patients with HIV-associated non-Hodgkin’s lymphoma. In this study, we found that a dose-modified oral regimen of combination chemotherapy was effective and safe with a low rate of treatment-related mortality.17 Based on these findings, a randomized clinical trial comparing this oral...
regimen with parenteral therapy with cyclophosphamide intravenously (IV) on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone orally on days 1-5 was launched in SSA (randomized, phase II trial of CHOP vs. oral chemotherapy with concomitant antiretroviral therapy in patients with HIV-associated lymphoma in sub-Saharan Africa; ClinicalTrials.gov identifier: NCT01775475). The results from this multicenter study are forthcoming and importantly demonstrate the role of locally relevant research with widespread implications.

Although HIV-associated malignancies are disproportionately represented in SSA, breast cancer remains among the most common cancers in SSA where it is characterized by advanced stage at diagnosis and poor survival. Despite the increasing investment in cancer care in Uganda and other countries in SSA, survival rates for breast cancer are still markedly lower than those in resource-rich countries.

The Breast Health Global Initiative (BHGI) and the National Comprehensive Cancer Network (NCCN) have published resource-stratified diagnostic and treatment guidelines for low- and middle-income countries. Even in limited-resource settings, the BHGI advocates for the determination of estrogen receptor (ER) status via immunohistochemistry (IHC). Until recently, access to key cancer diagnostic services including locally available diagnostics to detect the presence of hormone receptors (ER and progesterone receptor [PR]) and human epidermal growth factor receptor 2 (HER2) was not readily available in Uganda.

Treatment for breast cancer in Uganda primarily consists of cytotoxic, parenteral therapy and includes cyclophosphamide, methotrexate, and 5-fluorouracil (cyclophosphamide, methotrexate, and fluorouracil [CMF]) given IV on days 1 and 8 of a 28-day cycle or cyclophosphamide (orally days 1-14), doxorubicin (IV days 1 and 8), and 5-fluorouracil (days 1 and 8) (cyclophosphamide, doxorubicin, and fluorouracil) administered either every 21 or 28 days. Additionally, a regimen of IV doxorubicin and cyclophosphamide given every 3 weeks followed by a taxane (paclitaxel or docetaxel) has recently come into use in early-stage disease. Each of these regimens are consistent with guidance from the NCCN harmonized guidelines.

As illustrated by our previous work on AIDS-related non-Hodgkin’s lymphoma and the need for locally informed clinical decision making, an all-oral adjuvant chemotherapeutic regimen for breast cancer may be more practical than parenteral therapy given the limited availability of central intravenous access, the severe toxicities, and increased costs and logistics associated with IV drug delivery. Over a decade ago, the UCI entered a partnership with the Fred Hutchinson Cancer Research Center (Seattle, WA) to strengthen training and cancer research in Uganda. The mission of this collaboration is to strengthen research capacity, conduct research to reduce the burden of cancer-related morbidity and mortality, and train the next generation of Ugandan clinical researchers.

The UCI, which cares for up to 6,000 patients with newly diagnosed breast cancer annually, including approximately 700 women with breast cancer, provides a unique opportunity to answer locally relevant questions on the diagnosis and treatment of women with breast cancer. Through the collaboration between the UCI and the Fred Hutch Cancer Research Center, we have conducted over 25 research projects enrolling over 7,000 patients with a nearly 90% participation rate.

Building on this collaboration and with support from GlaxoSmithKline’s Africa Non-Communicable Disease Open Lab, we initiated a breast cancer clinical trial with both diagnostic and treatment components at the UCI. Specifically, we aimed to evaluate the potential to use widely available PCR-based molecular technology to improve the diagnosis of breast cancer, and additionally, we designed a companion trial to determine the feasibility of an oral neoadjuvant treatment regimen, consisting of
cyclophosphamide, methotrexate, and capecitabine, among Ugandan women with locally advanced breast cancer. In this paper, we will focus on the collaborative efforts of the diagnostic clinical trial, preliminary results, and lessons learned, all of which, we believe, will be of relevance and importance to colleagues engaged in clinical trials in SSA.

METHODS

For the diagnostic component of this ongoing study, all women > 18 years of age, independent of clinical stage, undergoing a diagnostic assessment for suspected breast cancer at either Mulago Hospital or the UCI are eligible for screening. After informed consent is obtained (in either English or Luganda), the surgeon obtains a biopsy specimen. Specimen collection, preparation, and processing are performed using standard operating procedures, which specify the accurate identification and gross description of the specimen and the prompt transfer of specimens from the surgical suite to the pathology lab. Specimens are divided and processed (fresh frozen and formalin-embedded). Only those patients with a histologically confirmed diagnosis of breast cancer are subsequently enrolled in the diagnostic study.

A formalin-fixed paraffin-embedded specimen is used for quantitative RT-PCR, using a validated assay for the detection of the ER, PR, and HER2. Receptor expression levels measured by RT-PCR are expressed as relative quantity (RQ) compared with housekeeping genes (CALM2). The RQ was therefore analyzed for any changes in gene expression in each individual sample relative to the reference gene. The RQ ranged between 0 and 1 with higher values consistent with higher expression of the respective receptors. The RQ cutoff points for each receptor were prespecified by a validated primer set (QuantiTect; Quiagen, Hilden, Germany).

Additionally, unstained slides are sent to the Fred Hutchinson Cancer Research Center to perform IHC for ER, PR, and HER2. The HER2 IHC results are dichotomized as negative (score 0 or 1 + or 2 +) or positive (3 +). The receiver operating characteristic analysis is applied to compare RT-PCR with IHC (the gold standard).

All studies performed under the auspices of this collaboration receive regulatory approval from the institutional review boards at the Fred Hutchinson Cancer Research Center UCI, the Uganda National Council for Science and Technology, and the Uganda Presidents Research Office in a sequential manner.

PRELIMINARY RESULTS

We analyzed interim data (anticipated N = 100 of an ongoing study) from 32 women of age 35-56 years (median, 48) who participated in the diagnostic component of the study. The majority of women (25, 78%) presented with advanced stage disease. Of the 32 cancers, 18 were ER+ (56%), 10 were PR+ (31%), and 9 were HER2+ (28%) per IHC; 8 (25%) were triple negative. From receiver operating characteristic analysis, the areas under the curve (95% CI) were 0.94 (0.85 to 1.0), 0.95 (0.89 to 1.0), and 0.76 (0.58 to 0.94) for ER, PR, and HER2, respectively. Selected sensitivity and specificity were 89% and 100% for ER (RQ ≥ 0.085), 100% and 86% for PR (RQ ≥ 0.0019), and 60% and 100% for HER2 (RQ ≥ 0.36), respectively (Table 1).

The study was suspended to accrual secondary to restrictions in place for COVID-19. We anticipate resuming study accrual once the COVID-19 restrictions are lifted.

DISCUSSION

Beginning with the seminal observations from Sir Albert Cook and Sir Denis Burkitt, clinical cancer research in Uganda has been locally relevant and pragmatic and has improved the standard of care of patients living in Uganda and globally. The development of the UCI was facilitated, in part, so that clinical trials could be conducted locally and the landscape of cancer clinical trials in Uganda remains robust. A recent paper by Gopal reviewed the critical features of cancer clinical trials in Africa, including the need to address a malignancy of high burden locally and the ability to generate novel data specific to the region (but that may be applied more broadly), which yield a favorable cost-benefit ratio. Our current research on breast cancer is in keeping with this mission.

 Ideally, cancer clinical trials should be entirely conducted in Uganda and elsewhere in SSA. This current study used the laboratory research infrastructure of both the UCI and the Fred Hutchinson Cancer Research Center. Given the need to determine the test characteristics of a novel method, comparison with a gold standard was necessary. We envision that future similar studies can entirely be conducted locally; however, given the need to compare the PCR results with IHC and the lack of widespread availability of IHC in Uganda at the time of study initiation, such a laboratory collaboration was necessary.

Our study was motivated by both the need for descriptive data on the local prevalence of ER, PR, and HER2 positivity in tumors among Ugandan women with breast cancer and the need to improve diagnostic and treatment options.

TABLE 1. Receiver Operating Characteristic Analysis (RT-PCR vs IHC)

| Receptor | AUC (95% CI) | RQ Cutoff Point | Sensitivity | Specificity |
|----------|-------------|----------------|-------------|-------------|
| ER       | 0.94 (0.85 to 1.0) | ≥ 0.085 | 89% | 100% |
| PR       | 0.95 (0.89 to 1.0) | ≥ 0.0019 | 100% | 86% |
| HER2     | 0.76 (0.58 to 0.94) | ≥ 0.36 | 60% | 100% |

Abbreviations: AUC, area under the curve; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; RQ, relative quantity.
A systematic review, which assessed 26 studies from SSA and incorporating nearly 5,000 women, found vast heterogeneity with the majority of estimates of ER-positive disease ranging from 20% to 70%.

Only two small studies were from Uganda, and the data regarding receptor status in Uganda have been mixed. In a study of 65 patients, researchers found that nearly two thirds of samples lacked ER expression; a subsequent study of 45 patients revealed that ER was positive in 60% of specimens. Using IHC in determining breast cancer receptor status is resource-intensive and requires expensive reagents, equipment, and trained personnel. Additionally, the preanalytic handling of the tumor specimen can highly affect results, causing false negative results from mishandling of the specimen and improper fixation time. An accurate determination of receptor status is essential to guide therapeutic decision making, yet this information has not been reliably available in many parts of SSA. Although additional validation is necessary (including the completion of our trial), our preliminary results indicate that the test characteristics of RT-PCR using a platform readily available throughout SSA are promising. Although there are variations in cost, we estimate that the costs associated with RT-PCR are less than half of the costs associated with IHC in the detection of ER, PR, and HER2. Although the laboratory technician time is comparable for both diagnostic tests, RT-PCR precludes much of the specimen handling and processing costs associated with IHC. Additionally, using RT-PCR allows for batching of samples in a cost-efficient manner. Given the wide accessibility of RT-PCR and endocrine therapy for breast cancer in SSA, as well as the recent inclusion of trastuzumab in the WHO’s Essential Medicines List, accurately determining breast cancer receptor status has both prognostic and therapeutic implications.

Clearly, increased availability and accessibility of diagnostic measures is necessary but insufficient to reduce the morbidity and mortality of breast cancer in SSA. In a study of 188 patients with breast cancer in Nigeria, 80% of women did not complete chemotherapy in part because of unavailability of drugs and the lack of transportation to the treatment facility. As such, other options, including effective oral regimens that have the potential to remove some of the barriers to care, are necessary.

In the midst of this study, the severe acute respiratory syndrome coronavirus 2, a novel coronavirus first identified in Wuhan, China, in December 2019 and the agent of the global COVID-19 pandemic emerged. To curb the transmission of severe acute respiratory syndrome coronavirus 2, the Government of Uganda instituted physical distancing measures and restrictions on the new enrollment into clinical trials (similar measures were in place in Seattle, WA). Patients who were enrolled on the intervention trial continued to receive the oral CMF, with some modifications to the scheduling; however, the study was understandably suspended to new participants. The potential role of oral chemotherapy, which precludes the need for visits to an infusion center, is likely more advantageous in the setting of restricted physical mobility. Indeed, colleagues in Seattle have prescribed this oral regimen of CMF during the COVID-19 pandemic, balancing the risks of travel for infusion therapy with the potential benefits of alternative regimens.

Given the multiple barriers to adequate IHC services, including cost, specimen handling, interpretation, and scarcity of trained pathologists, alternate diagnostic methods are needed. Although preliminary, our data suggest that RT-PCR, which is widely available in Uganda and other countries in SSA, compares favorably with IHC and can inform breast cancer treatment decision making. Patients with tumors expressing ER are typically treated with 5-10 years of endocrine therapy (eg, tamoxifen and aromatase inhibitors) to further reduce the risk of disease recurrence. Reliable ER testing allows withholding of endocrine therapy (and its associated cost and toxicities) in an ER-negative patient. Patients with tumors expressing HER2 derive benefit from adjuvant HER2-targeted therapy (eg, trastuzumab) for 1 year, although shorter treatment durations may also be beneficial. However, despite being on the WHO Model List of Essential Medicines, HER2-targeted therapy is not readily available or affordable in resource-limited settings. Fortunately, biosimilar agents appear to be equally effective and we expect accessibility and availability for these agents to increase in resource-limited regions. Notably, each of the drugs in the oral CMF regimen are on the List of Essential Medicines, readily available, and recommended by both the National Comprehensive Cancer Network (NCCN) and the BHGI. Although the accrual to the modified CMF clinical trial has been slow, we remain optimistic about the utility of oral chemotherapy in this setting.

Innovative diagnostic and treatment strategies are required to address the burden of breast cancer that is increasing throughout SSA. Given the costs, infrastructure, and trained personnel associated with IHC, alternative testing options (including RT-PCR as tested in our study) may provide an expedited and cost-effective method to determine receptor testing in breast cancer. Alternative treatment options that can reduce the requirement for travel to the infusion center, and potentially reduce the need for costly supportive care medications, are also worthy of exploration. Clinical trials conducted in the local setting are critical to determining optimal strategies for effective breast cancer management in SSA.
REFERENCES

1. Ferlay JSH, Bray F, Forman D, et al: Cancer incidence and mortality worldwide: IARC 2008 [GLOBOCAN 2008 v1.2]. http://globocan.iarc.fr
2. Yarney J, Vanderpuye V, Clegg Lamphey JN: Hormone receptor and HER-2 expression in breast cancers among sub-Saharan African women. Breast J 14:510-511, 2008
3. Stark A, Kleer CG, Martin I, et al: African ancestry and higher prevalence of triple-negative breast cancer: Findings from an international study. Cancer 116:4926-4932, 2010
4. McCormack VA, Joffe M, van den Berg E, et al: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: A case series. Breast Cancer Res 15:R84, 2013
5. Ly M, Antoine M, Dembele AK, et al: High incidence of triple-negative tumors in sub-Saharan Africa: A prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257-263, 2012
6. Ibrahim NA, Oulada MA: Socio-demographic factors and reasons associated with delay in breast cancer presentation: A study in Nigerian women. Breast 21:416-418, 2012
7. Eng A, McCormack V, dos-Santos-Silva I: Receptor-defined subtypes of breast cancer in indigenous populations in Africa: A systematic review and meta-analysis. PLoS Med 11:e1001720, 2014
8. Dickens C, Joffe M, Jacobson J, et al: Stage at breast cancer diagnosis and distance from diagnostic hospital in a periurban setting: A South African public hospital case series of over 1,000 women. Int J Cancer 135:2173-2182, 2014
9. Epstein MA, Barr YM: Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet 1:252-253, 1964
10. Epstein MA, Achong BG, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703, 1964
11. Burkitt D, Hurt MS, Wright DH: The African lymphoma: Preliminary observations on response to therapy. Cancer 18:399-410, 1965
12. SIR Albert Cook, C.M.G., O.B.E. M.D. Br Med J:1:1021-1022, 1951
13. Burkitt D: A lymphoma syndrome in African children. Ann R Coll Surg Engl 30:211-219, 1962
14. Orem J, Mbitde EB, Lambert B, et al: Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7:166-175, 2007
15. Olweny CL, Toya T, Katongole-Mbidde E, et al: Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36:1250-1257, 1975
16. Olweny CL, Katongole-Mbidde E, Kiru C, et al: Childhood Hodgkin's disease in Uganda: A ten year experience. Cancer 42:787-792, 1978
17. Mwanda WO, Orem J, Fu P, et al: Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol 27:3480-3488, 2009
18. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol 5:1749-1768, 2019
19. Joko-Fru WY, Miranda-Filho A, Soerjomataram I, et al: Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. Int J Cancer 146:1208-1218, 2020
20. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018

AUTHOR CONTRIBUTIONS

Conception and design: All authors
Financial support: Manoj P. Menon
Administrative support: Manoj P. Menon
Collection and assembly of data: Manoj P. Menon, Nixon Niyonzima, Jackson Orem
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Manoj P. Menon

Research Funding: Cepheid (Institution) GSK Africa Open Lab (Institution), Conquer Cancer Foundation of the American Society of Clinical Oncology

Julie Gralow

Consulting or Advisory Role: Novartis, Genentech, Pfizer, Merck, Puma Biotechnology, Sandoz, AstraZeneca, Immunomedics, Genomic Health

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

Research Sponsor: GSK Africa NCD Open Lab, Conquer Cancer Foundation of the American Society of Clinical Oncology.

We would like to acknowledge the assistance of Scott Adams, Alex Bakenga, Diana Basemera, Corey Casper, Sarah Ewart, Cristin Gordon-McLean, David Kasozi, Eric Konnick, Kelvin Mubiru, Yusuf Mulumba, Catherine Muwonge, Lazarus Okoche, Robert Pierce, and Aimee Schantz.
21. Anderson BO, Carlson RW: Guidelines for improving breast health care in limited resource countries: The Breast Health Global Initiative. J Natl Compr Cancer Netw 5:349-356, 2007
22. Carlson RW, Larsen JK, McClure J, et al: International adaptations of NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 12:643-648, 2014
23. Eniu A, Carlson RW, El Saghir NS, et al: Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. Cancer 113:2269-2281, 2008 (8 suppl)
24. Shyyan R, Sener SF, Anderson BO, et al: Guideline implementation for breast healthcare in low- and middle-income countries: Diagnosis resource allocation. Cancer 113:2257-2268, 2008 (8 suppl)
25. National Comprehensive Cancer Network: NCCN harmonized guidelines for sub Saharan Africa—Breast cancer 2019. https://www.nccn.org/professionals/physician_gls/pdf/breast_harmonized-africa.pdf
26. Albain KS, Barlow WE, Ravdin PM, et al: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:2055-2063, 2009
27. Okello CD, Ddungu H, Omoding A, et al: Capacity building for hematologic malignancies in Uganda: A comprehensive research, training, and care program through the Uganda Cancer Institute-Fred Hutchinson Cancer Research Center collaboration. Blood Adv 2:8-10, 2018 (suppl 1)
28. Menon M, Oram J, Adams S, et al: ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC. J Clin Oncol 38:e19009, 2020
29. Gopal S: Cancer trials in sub-Saharan Africa: Aligning research and care. PLoS Med 14:e1002351, 2017
30. Roy I, Othieno E: Breast carcinoma in Uganda: Microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med 135:194-199, 2011
31. Nalwoga H, Ames JB, Wabinga H, et al: Frequency of the basal-like phenotype in African breast cancer. APMIS 115:1391-1399, 2007
32. Adisa AO, Gukas ID, Lawal OO, et al: Breast cancer in Nigeria: Is non-adherence to chemotherapy schedules a major factor in the reported poor treatment outcome? Breast J 16:206-207, 2010
33. Zhu N, Zhang D, Wang W, et al: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727-733, 2020
34. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen-receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
35. Moja L, Tagliaure L, Balduzzi S, et al: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev CD006243, 2012
36. WHO model lists of essential medicines. 2017. http://www.who.int/medicines/publications/essentialmedicines/en/index.html
37. Rugo HS, Barne A, Walter CF, et al: Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. JAMA 317:37-47, 2017
38. Carlson RW, Scavone JL, Koh WJ, et al: NCCN framework for resource stratification: A framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw 14:961-969, 2016
39. Anderson BO, Shyyan R, Eniu A, et al: Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12:S3-S15, 2006(suppl 1)